A Phase 1 interventional study of Berobenatide in Overweight and/or Obesity and Healthy Participants, sponsored by Pfizer. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.
The study involves multiple clinic visits at a study site over the length of the study.
3,767 studies on the registry are indexed under Overweight; 863 are open to participants now.
This study's planned enrollment of 144 is above the median of 73 across 3,263 interventional studies indexed under Overweight.
Browse Overweight studies →Pfizer is the lead sponsor of 3,323 studies on the registry; 145 are open to participants now.
Of its 597 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Dosing subcutaneous berobenatide Reference Delivery System 1
Drug: Berobenatide
Dosing subcutaneous berobenatide Reference Delivery System 2
Drug: Berobenatide
Dosing subcutaneous berobenatide Test Delivery System 1
Drug: Berobenatide
Dosing subcutaneous berobenatide Test Delivery System 2
Drug: Berobenatide
Solution for Injection
Also known as: PF-08653944
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Berobenatide
Time frame: Up to 85 days
PK: Maximum Observed Concentration (Cmax) of Berobenatide
Time frame: Up to 85 days
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 85 Days
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berobenatide